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Desflurane in modern anaesthetic practice: walking on thin ice(caps)? 
 
The third-generation volatile anaesthetic agents desflurane and sevoflurane were introduced 
into clinical practice in 1990 in response to the perceived need for rapid return of 
consciousness after ‘ambulatory’ surgery.1 Initially marketed by two competing 
pharmaceutical companies, their relative merits have been debated for three decades.2 Of 
the two, desflurane has a lower solubility in blood and therefore the fastest offset, providing 
a rapid emergence, which is more notable in obese patients and following prolonged 
anaesthesia.2 Furthermore, some authorities (including the United States’ Food and Drug 
Administration (FDA)) have deemed desflurane to be more suitable than sevoflurane for low-
flow anaesthesia, as it undergoes only negligible metabolism and minimal reaction with soda 
lime.3 However, desflurane has several well-known disadvantages, including a pungent odour 
(making it a respiratory irritant), lower potency, and environmental impacts related to its 
manufacture, administration and discharge into the atmosphere, calling into question its 
continued use as a general anaesthetic agent 1-2,4 
 
The clinical impacts of desflurane 
 
Total intravenous anaesthesia (TIVA) and regional anaesthesia are becoming increasingly 
popular for environmental and clinical reasons, with regional anaesthesia  advocated 
preferentially during the current coronavirus crisis to preserve drug stocks and avoid aerosol-
generating procedures.5,6 However, national studies suggest that the most common method 
of delivering general anaesthesia involves intravenous induction and inhalational 
maintenance.5,7 Mainly historical data indicates that desflurane’s faster elimination from the 
body facilitates rapid-turnover operating lists and may benefit some higher-risk patients, but 
there is scant clinical evidence to confirm these benefits in current anaesthetic practice. A 
recent observational study of over 100,000 cases by Zucco and colleagues, for example, found 
no difference in postoperative pulmonary complications between patients anaesthetised 
with sevoflurane and desflurane when adjusted for confounding factors.8 
 
One potential advantage of desflurane is the faster time to recovery of consciousness and 
tracheal extubation. However, whilst meta-analyses of randomised controlled trials (RCTs) 
have confirmed that this is consistently a statistically significant finding (table 1), the 
magnitude of this effect is minimal (only a few minutes in most circumstances), and it does 
not appear that this translates to shorter patient stays in the post-anaesthesia care unit 
(PACU).8-12,14 Furthermore, as pointed out by Macario and colleagues, because RCT study 
protocols tend to require the use of a constant concentration of general anaesthetic agent up 
to the point of wound closure, the common clinical practice of tapering the anaesthetic dose 
as the surgical stimulus reduces is not represented, and this may further reduce any ‘real 
world’ difference between agents.10 We contend that a trivially more rapid emergence from 
general anaesthesia with desflurane compared to sevoflurane may be of greater promotional 
benefit to the manufacturer than either clinical benefit to the patient or organisational 
benefit to surgical operating efficiency. 
 




Whilst many previous studies of desflurane have been concerned with its pharmacokinetic 
qualities, in the current issue of the British Journal of Anaesthesia, Ryu and colleagues focus 
on an important pharmacodynamic difference between volatile agents.15 In this meticulously-
controlled study, participants who were scheduled for arthroscopic knee surgery were 
randomised to receive an additional 35 minutes of anaesthesia before their operation with 
one minimum alveolar concentration (MAC) of either sevoflurane or desflurane, following a 
target-controlled induction with propofol and muscle relaxation with rocuronium. Perfusion 
index (a measure of peripheral perfusion derived from the pulse oximeter signal), mean 
arterial pressure (MAP) and heart rate were recorded every minute throughout the study 
period, which included a standardised noxious stimulus (tetany from a peripheral nerve 
stimulator) after 30 minutes of vaporiser adjustment and equilibration time. The desflurane 
group demonstrated a significantly higher perfusion index (indicating inferior peripheral 
perfusion) and a significantly lower MAP than the sevoflurane group. These findings, the 
authors suggest, indicate that desflurane has more potent vasodilatory properties than 
sevoflurane at an equivalent dose, at a magnitude that may be associated with harm.15 
 
Intraoperative hypotension is associated with adverse patient outcomes including mortality, 
acute kidney injury, myocardial infarction, and wound infection in settings including 
orthopaedic trauma, vascular, thoracic, and general surgery.16-19 Concerningly, these are all 
surgical specialties in which high-risk and prolonged operations are relatively commonplace 
and therefore the use of desflurane may be most tempting for clinicians. Furthermore, a 
survey of UK practice indicates that desflurane appears to be more commonly used in older 
patients, who are at higher risk of the complications of hypotension.7 The mean pre-
stimulation MAP in Ryu and colleagues’ desflurane group was 73mmHg, compared to 
81mmHg in the sevoflurane group.15 Though one MAC of volatile agent is arguably a higher 
dose of anaesthetic than was required given the lack of ‘surgical’ stimulation, these findings 
do have potential clinical significance. A recent systematic review by Wesselink and 
colleagues concluded that the risk of end-organ injury begins to increase at a MAP of 
<80mmHg for a duration >10 minutes.20 Whilst it cannot be determined if the (comparatively 
young and fit) participants in Ryu’s study came to any harm as patient outcomes were not 
assessed, this is a potentially important signal and requires further investigation in older and 
more comorbid populations.15 
 
 
The environmental impacts of volatile anaesthetic agents 
 
The environmental effects of inhaled anaesthetic agents were recognised before the 
introduction of sevoflurane and desflurane, though early focus was on the potential for 
chloride ions liberated by the ultraviolet photolysis of agents such as isoflurane (but not 
sevoflurane or desflurane) to contribute to the destruction of the ozone layer.1 Latterly 
however, attention has been brought to bear more prominently on the action of inhaled 
agents as ‘greenhouse gases’,4,21-24 contributing to anthropogenic global warming through 
radiative forcing i.e. the absorption of infrared radiation that would otherwise escape into 
space. The degree to which a substance released into the atmosphere contributes to global 
warming depends on two factors: firstly the radiative efficiency – the amount of infrared 
radiation absorbed, which is determined by the number and type of atomic bonds within the 
structure of the molecule, and secondly, whether there are any naturally-occurring molecules 
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(e.g. water vapour) that would otherwise absorb infrared radiation at the same 
wavelengths.22,23 
 
The global warming potential (GWP) of greenhouse gases differs over time, depending on the 
lifespan of the molecule, with more atmospherically-persistent molecules having a greater 
cumulative impact. The GWP20 and GWP100 express the global warming potential of a 
substance over 20 and 100 years, respectively, in comparison to the effect of an equal mass 
of carbon dioxide. In anaesthetic practice, the differences in molecular mass and potency 
between volatile agents can make comparison on the basis of GWP challenging. Özelsel and 
colleagues’ concept of carbon dioxide equivalencies (CDE) addresses this issue by multiplying 
the GWP by the mass of anaesthetic agent used per hour at a given MAC and fresh gas flow 
(table 2), thereby enabling a clinically relevant comparison.22 
 
[table 2 here] 
 
Though sevoflurane is generally considered to be the least damaging volatile anaesthetic from 
a climate change perspective, life cycle analysis has demonstrated that its GWP100 is 
approximately three orders of magnitude greater than an equivalent dose of propofol TIVA.4 
It is for this reason that the National Health Service Sustainable Development Unit has 
designated volatile anaesthetic agents, and desflurane in particular, to be a ‘carbon 
hotspot’.24 The difference between the GWP of anaesthetic agents is more pronounced at 
100 years than at closer time horizons, owing to the greater environmental persistence of 
desflurane. This raises the question of what time horizon should be used when making policy 
and practice decisions. Recently, It has been suggested that the 20- and 100-year time 
horizons underplay the atmospheric effects of volatile agents in the face of a pressing climate 
crisis, because their global warming effects will remain at their atmospheric release levels if 
their use continues unabated.22 Regardless of their comparative environmental impacts, both 
desflurane and sevoflurane have profound global warming impacts, such that anaesthetists 
seriously need to consider the default use of volatile agents for general anaesthesia.21 
 
Desflurane: a ‘triple bottom line’ approach 
 
Desflurane, then, has little evidence of important patient benefit, considerable 
environmental impacts at a time of climate crisis, and now appears to have evidence of 
potential for harm.4,8-15 Given these widespread drawbacks, anaesthetists have to question 
the rationale for its continued use. As with any practice, the risks and benefits associated with 
desflurane use can be conceptualised using the so-called ‘triple bottom line’ approach by 
considering impacts on ‘people’ (e.g. the patient, staff members and broader society), ‘planet’ 
(i.e. environmental sustainability) and the ‘public purse’ (i.e. healthcare finances).23,25  
 
People: 
Arguably, the most important element of decision-making in anaesthetic practice relates to 
patient safety. Here, there is little evidence of any benefit to desflurane, and the degree of 
hypotension demonstrated in Ryu’s study is a cause for concern, particularly in older or 
comorbid patients.8-15 In terms of quality of care, desflurane is consistently associated with 
more rapid emergence from anaesthesia and tracheal extubation, however these benefits are 
small in magnitude and do not lead to any improvement in discharge times.8-12,14 As a 
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consequence, these benefits are likely to be noticed only by the anaesthetic team, but not by 
the patient or operating theatre staff more generally. Although patient outcomes are of 
paramount importance for the anaesthetist, this does not mean that the effects of climate 
change on communities worldwide should be discounted.25 
 
Planet: 
Depending on the time horizon used, the GWP of desflurane is between five and twenty times 
more than that of sevoflurane4 Though technologies to capture and re-process desflurane 
have been developed and are currently being trialled in some healthcare institutions, these 
would have to be exceptionally efficient to overcome this magnitude of difference.21,23,25 
Likewise, although sevoflurane is not licensed for low flow anaesthesia in some countries 
despite evidence of the safety of this technique, even at fresh gas flows of 1-2l.min-1 it 
remains markedly less environmentally harmful than low-flow desflurane in terms of climate 
change.3,4 Furthermore, evidence supports the preferential use of total intravenous, or 




Desflurane is approximately one-third the potency of sevoflurane and, though it was initially 
less expensive whilst ‘on patent’ it is now typically more costly due to the market forces 
created by the wider availability of generic sevoflurane (240ml desflurane ~£90, 250ml 
sevoflurane ~£60; personal communication).1 Even accounting for the negligible metabolism 
and low solubility of desflurane, and its (minor) benefits in the speed of early recovery from 
anaesthesia, at an equal fresh gas flow and MAC desflurane has consistently been found to 
be more expensive than sevoflurane.26 Therefore, it is only in countries where sevoflurane is 
unlicensed for low-flow anaesthesia that a cost effectiveness argument could be made in 
favour of desflurane.3 It should be noted however, that the additional non-drug costs to 
healthcare institutions (e.g. heating the desflurane vaporiser) and public finances more 
broadly (e.g. as a consequence of global warming) are not accounted for in existing cost 
analyses.   
 
In conclusion, anaesthetists have a responsibility not only to care for the patient in front of 
them, but also to safeguard the health and welfare of future generations.21,25 Ryu et al.’s study 
in this issue of the British Journal of Anaesthesia adds to existing evidence aligning these two 
responsibilities through the discontinuation of desflurane use and manufacture.8,15  Individual 
anaesthetists, as well as the wider profession, can choose how to deliver general anaesthesia. 
We accept that inhalational anaesthetic agents may be appropriate in certain circumstances, 
but assumptions about the specific clinical benefits of desflurane based on its physiochemical 
properties are breaking down. In our opinion, the arguments against its use are now 
overwhelming. We strongly encourage anaesthetists who are still using desflurane to 
reconsider the evidence for its use, and ask themselves how they might transition to using 
less environmentally harmful alternatives. 
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Study Context Desflurane vs Sevoflurane Desflurane vs Propofol Notes 
  Emergence Extubation PACU 
Discharge 
Emergence Extubation PACU 
Discharge 
 
Gupta 20049 Adult patients. Ambulatory surgery - <1 min - <1 min + 6 mins - 1.3 mins NR NR Less PONV in propofol group 
Macario 200510 Adult and paediatric patients. 
Ambulatory and inpatient surgery 
-1.7 mins -1.3 mins NS NR NR NR No difference in PONV between groups 
Liu 201511 Patients with BMI > 30 kg.m-2. 
Ambulatory and inpatient surgery  
-3.09 mins -3.88 mins +1.28 mins - 10.7 min - 13.2 min NR No difference in PONV or analgesic requirement 
between groups 
Stevanovic 201512 Adult patients. Laryngeal mask 
airway 
-3.81 mins -0.7 mins* NR NR NR NR No difference in cough or laryngospasm 
between groups 
Lim 201613 Paediatric patients. Ambulatory 
surgery. 
-2.74 mins -2.21 mins NR NR NR NR No difference in incidence or severity of 
emergence agitation between groups 
Guo 201714 Paediatric patients. Ambulatory 
and inpatient surgery  
NS -3.27 mins NS NS -3.83 mins NS No difference in PONV or analgesic requirement 
between groups. Less emergence agitation with 
propofol vs desflurane or sevoflurane.  
 
Table 1: Meta-analyses of RCTs comparing time to emergence, tracheal extubation and PACU discharge of patients anaesthetised with desflurane, sevoflurane and 





 GWP1 CDE1 (kg.h-1) GWP20 CDE20 (kg.h-1) GWP100 CDE100 (kg.h-1) 
Sevoflurane 4285  21.43 796 3.980 216 1.08 
Desflurane 8526 107.45 5513 69.49 1778 22.42 
 
Table 2: Global warming potentials (GWP) of sevoflurane and desflurane, at 1, 20 and 100 years, and corresponding carbon dioxide equivalents (CDE) per hour of 
anaesthesia at 1 MAC and 0.5l.min-1 fresh gas flow. One hour of desflurane use at 1MAC and 0.5l.min-1 fresh gas flow has a GWP100 equivalent to 22.42 kg CO2. This is 
comparable to driving 90 miles in a typical UK family car, and over 20 times greater than if sevoflurane were used. Data adapted from Özelsel et al.22 
 
